Loading clinical trials...
Loading clinical trials...
This is a single-center, single-arm, open label investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of advanced pancreatic cancer.
This is a single-center, single-arm, open label investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of advanced pancreatic cancer. The study is planned to enroll 10 subjects. The entire study consists of a screening period of up to 28 days, treatment period, and a follow-up period (safety follow-up 28 days after the final study dose and survival follow-up once every 3 months).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Xiangya Hospital of Central South University
Changsha, Hunan, China
Start Date
March 12, 2025
Primary Completion Date
October 31, 2025
Completion Date
December 31, 2025
Last Updated
March 10, 2025
10
ESTIMATED participants
Oncolytic virus VRT106
DRUG
Chemotherapy
DRUG
Lead Sponsor
Xiangya Hospital of Central South University
Collaborators
NCT05053971
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions